CLL14 study five-year results: Significantly superior efficacy for Ven-Obi
Five-year results from the ongoing CLL14 study, comparing venetoclax-obinutuzumab (Ven-Obi) to chlorambucil-obinutuzumab (Clb-Obi) in patients with previously untreated chronic lymphocytic leukemia (CLL), continue to demonstrate superior efficacy with longer progression-free survival (PFS) in patients receiving Ven-Obi. Let the primary investigator Dr. Othman Al-Sawaf update you in this MEDtalk.
Get access to the article
If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.